asxan.ai Agents Hub

Weight Management

Evidence Stack

Metabolic syndrome · body composition · lean-mass preservation

Evidence-first metabolic and body-composition stack — what the human-evidence record actually shows for the ingredients most associated with weight management, including the standalone-vs-complex-formulation caveats and the honest nulls. Obesity (ICD-10 E66) is a clinical condition; this is mechanism and evidence mapping, not medical advice. Substantial body-weight reduction requires lifestyle, dietary, behavioral, and where appropriate medical management — discuss any weight-management strategy with your prescribing physician and registered dietitian. All PubMed identifiers are verified against PubMed before inclusion; cross-market regulatory claims appear verbatim per their authorising authority (FDA · EFSA · ANVISA · TGA).

Last reviewed · How we assess evidence →

Quick Summary

  • Obesity (ICD-10 E66) is a clinical condition requiring lifestyle, dietary, behavioral, and where appropriate medical management. This page maps mechanism and biomarker evidence for ingredients commonly studied in metabolic-syndrome and body-composition contexts — it is not a weight-loss program.
  • Fucoxanthin has the strongest direct evidence in this related-ingredients list. López-Ramos 2023 RCT (PMID 37405785) reported metabolic-syndrome composite improvement in a standalone fucoxanthin trial. UCP1 thrifty-allele interaction in Mikami 2017 (PMID 28620480) is one of the more reproducible nutrigenomic signals in the carotenoid literature. NAFLD subgroup signals come from formulation-complex trials (Abidov 2010 Xanthigen PMID 19840063 and Shih 2021 LMF-HSFx PMID 33809062), which should be read with the complex-formulation caveat.
  • Yeast protein supports lean-mass preservation during energy restriction. PDCAAS near 1.00 and DIAAS estimate 0.82 to 1.00 (Cao 2024 PMID 39303477; Qiao 2025 PMID 40934397, INFOGEST). Direct human muscle-endpoint RCT in yeast protein is currently limited — the primary human evidence is honest-small, with mycoprotein analogy (PMID 32438401) and yeast β-glucan literature (PMID 33900466) transparently labeled as separate, adjacent evidence categories.
  • Berberine — preliminary / emerging here. The broader literature (Cochrane and others) carries AMPK-pathway and glucose-management evidence.
  • This is not medical advice. No supplement on this page substitutes for medical management of obesity or related conditions. Discuss any weight-management strategy with your prescribing physician and registered dietitian.

The Evidence Stack

The "evidence" column below describes the strength and direction of the outcome evidence in qualitative terms — well-established, robust, moderate/mixed, preliminary/emerging, or null/negative. The S/A/B/C tier that grades how extensively an ingredient is studied (its evidence volume) lives on each linked ingredient page, not here.

Ingredient Weight / metabolic evidence (qualitative) Key Trial / Meta-analysis asxan.ai page
Fucoxanthin Moderate — robust for the standalone metabolic-syndrome composite; preliminary / emerging for the NAFLD subgroup (complex-formulation caveat); not a standalone body-weight agent López-Ramos 2023 PMID 37405785 (standalone met-syn RCT); Abidov 2010 PMID 19840063 (Xanthigen complex); Mikami 2017 PMID 28620480 (UCP1 genotype interaction); Shih 2021 PMID 33809062 (LMF-HSFx NAFLD complex) /ingredients/fucoxanthin/
Yeast Protein Moderate / mixed — robust on PDCAAS / DIAAS protein-quality biomarkers and ex-vivo gut-barrier non-inferiority; preliminary / emerging on direct human muscle-endpoint RCT Cao 2024 PMID 39303477 (PDCAAS ~1.00); Qiao 2025 PMID 40934397 (INFOGEST); Van den Abbeele 2026 PMID 41568030 (gut barrier non-inferior to whey/soy) /ingredients/yeast-protein/
Berberine Preliminary / emerging — broader literature carries AMPK / glucose signals Cochrane and broader-literature AMPK / glucose-management evidence /ingredients/berberine/

How It Works

Each ingredient engages metabolic and body-composition biology by a different route — fucoxanthin through UCP1 thermogenesis and lipid metabolism, yeast protein through amino-acid completeness and lean-mass preservation, berberine through AMPK activation; protein adequacy and dietary fiber form the structural pattern on which all of these operate.

Fucoxanthin — UCP1 thermogenesis and lipid metabolism. Fucoxanthin is a brown-algae-derived xanthophyll carotenoid; its metabolite fucoxanthinol engages uncoupling protein 1 (UCP1) expression in white-adipose-tissue depots, supporting non-shivering thermogenesis. The Mikami 2017 RCT (PMID 28620480) reported HbA1c reduction interacting with the UCP1 thrifty-allele genotype — one of the more reproducible nutrigenomic signals in the carotenoid literature. NAFLD signals are reported in complex formulations (Abidov 2010 Xanthigen PMID 19840063 — fucoxanthin + pomegranate seed oil; Shih 2021 LMF-HSFx PMID 33809062 — low-molecular-weight fucoidan + high-stability fucoxanthin), which should not be over-extrapolated to standalone fucoxanthin. See /ingredients/fucoxanthin/#mechanism.

Yeast protein — amino-acid spectrum and gut-microbiome modulation. Saccharomyces cerevisiae-derived protein has PDCAAS near 1.00 and DIAAS estimate 0.82 to 1.00 (Cao 2024 PMID 39303477; Qiao 2025 PMID 40934397). Van den Abbeele 2026 ex-vivo gut-microbiota study (PMID 41568030) showed non-inferior gut-barrier and SCFA endpoints versus whey and soy. The mechanism of relevance to weight management is lean-mass preservation during energy restriction (Miller 2014 PMID 24724774 supports 1.6 to 2.4 g/kg/day) — yeast protein offers a complete amino-acid-spectrum option in plant-fermentation form.

Berberine — AMPK activation and glucose pathway. Berberine is a plant alkaloid researched as an AMPK activator with glucose-management signals in the broader literature. Treat the mechanism as biochemically plausible; this page does not reproduce specific PMIDs from outside the asxan.ai evidence base.

Whey protein and body composition (cross-link). Although whey is not in this page's related-ingredients list, it is part of the broader weight-management evidence base. Baer 2011 (PMID 21677076) — 90 free-living overweight or obese adults randomized to 56 g/day of whey, soy, or maltodextrin for 23 weeks (no prescribed exercise, no prescribed caloric restriction). Whey arm lost ~1.8 kg body weight and ~2.3 kg fat mass vs maltodextrin; soy did not differ from maltodextrin. See /ingredients/whey-protein/ for the full chronic body-composition signal.

Endogenous GLP-1 release from whey pre-load (mechanism cluster). Jakubowicz 2014 (PMID 25005331) reported that a whey pre-load before breakfast in type 2 diabetes increased post-prandial GLP-1 and GIP and reduced glucose excursion. Smith 2022 (PMID 35618446) extended this signal to 7-day free-living CGM time-in-range with a whey premeal shot. These are endogenous GLP-1/incretin signals from a food protein — they are mechanistically related to, but categorically distinct from, prescription GLP-1 receptor agonist medications (semaglutide, tirzepatide). See the trials section boundary disclosure.

Soluble fiber, viscosity, and satiety cluster. Reynolds 2019 Lancet (PMID 30638909) is the large prospective and trial-pooled evidence base linking dietary-fiber adequacy to cardiometabolic and body-weight endpoints. Jovanovski 2018 (PMID 30239559) reported psyllium LDL-C reduction of about 0.33 mmol/L at approximately 10.2 g/day. Van der Schoot 2022 (PMID 35816465) is the systematic review and meta-analysis of fiber supplementation for chronic constipation (psyllium and pectin the only RCT-supported forms). These fiber signals operate on satiety, glycemic response, and lipid endpoints — not on direct fat loss — but they are part of the structural dietary pattern that supports weight management.

Protein adequacy in older adults (sarcopenia overlap). Cermak 2012 (PMID 23134885) is the meta-analysis that established the protein-plus-resistance-training framework in older adults, supporting the 1.6 g/kg/day threshold that Morton 2018 (PMID 28698222) later confirmed across the full adult age range. For older adults during weight loss, the lean-mass-preservation priority is elevated relative to younger adults — protein adequacy is the single most cost-effective intervention.

Body systems engaged: Endocrine & Metabolic · Body Composition · Digestive & Gut. Mechanism tags: AMPK activation · Gut microbiota modulation · mTOR regulation.

What the Trials Show — Including the Nulls

Yeast protein direct human muscle-endpoint evidence is currently limited. One 8-week trial (n=79) is published in a journal not indexed by PubMed. The PDCAAS / DIAAS in-vitro data (Cao 2024 PMID 39303477; Qiao 2025 PMID 40934397) establish protein-quality equivalence on biomarker terms, not on direct human MPS endpoints.

Berberine evidence here is preliminary / emerging. Broader literature does carry AMPK-pathway and glucose-management signals, including meta-analytic data — but this page does not reproduce those specific PMIDs because they sit outside the asxan.ai evidence base.

Supplement-level GLP-1 signals are not equivalent to prescription GLP-1 receptor agonists. Whey-driven endogenous GLP-1/GIP release (Jakubowicz 2014 PMID 25005331; Smith 2022 PMID 35618446) operates on post-prandial peaks measured in picomoles per liter and resolves within hours; semaglutide and tirzepatide are pharmacological agonists with sustained receptor engagement and a different magnitude of weight-loss effect. Do not characterize whey, fiber, or any nutrition signal as an equivalent or alternative to GLP-1 medication. The GLP-1 Companion page addresses the medication-adjunct nutrition question explicitly.

Fiber is not a fat-loss agent. The Reynolds 2019 Lancet systematic review (PMID 30638909) and Jovanovski 2018 psyllium LDL-C meta (PMID 30239559) describe cardiometabolic and lipid endpoints. Fiber supports satiety and glycemic response, which can support adherence to a caloric strategy — but fiber alone, in the absence of sustained caloric balance, does not cause clinically meaningful weight loss. Van der Schoot 2022 (PMID 35816465) is specifically about chronic constipation, not weight management.

Stacking & Timeline

Mechanistic pairings are plausible but rarely backed by head-to-head synergy trials; the structural synergy in the literature is protein + caloric deficit, not ingredient + ingredient. Realistic timelines run from weeks (metabolic-syndrome composite, body-composition signals) to months (clinical weight-loss thresholds, which no ingredient delivers as a standalone).

Mechanistic pairs

Protein adequacy + caloric deficit · the body-composition pair. Adequate protein during energy restriction (1.6 to 2.4 g/kg/day per Miller 2014 PMID 24724774) supports the lean-mass preservation that determines the quality of weight loss. This is the structural synergy in the literature — protein + deficit, not ingredient + ingredient.

Fucoxanthin + omega-3 · metabolic-syndrome composite pair (mechanism only). Fucoxanthin engages UCP1 thermogenesis and metabolic-syndrome composite markers; omega-3 engages hepatic VLDL secretion (TG lowering) and inflammatory markers. The metabolic-syndrome composite-marker overlap is mechanistically logical; head-to-head clinical synergy in standalone formulations is not established. See /ingredients/omega-3/.

Berberine + dietary fiber · AMPK + microbiome pair (mechanism only). Broadly discussed in the literature; head-to-head clinical synergy is not established.

Whey pre-load + soluble fiber · incretin and satiety stack (mechanism only). Whey pre-load engages endogenous GLP-1/GIP release post-prandially (Jakubowicz 2014 PMID 25005331; Smith 2022 PMID 35618446); soluble fiber slows gastric emptying and modulates post-prandial glucose excursion (Reynolds 2019 PMID 30638909; Jovanovski 2018 PMID 30239559). The mechanistic logic — two upstream satiety and glycemic levers stacked before a meal — is plausible and grounded in single-ingredient trials; head-to-head clinical trials of the combination versus either alone are not curated on asxan.ai.

Protein adequacy + resistance training · the older-adult body-composition pair. Cermak 2012 (PMID 23134885) established the meta-analytic case for protein plus resistance training in older adults; Morton 2018 (PMID 28698222) extended the threshold framework (1.6 g/kg/day) across adult age. For weight loss in adults over 60, this pair is the structural anchor for preserving lean mass and physical function. See /lifestyles/senior-60-plus/.

When to see results — realistic timeframes

4 to 12 weeks · metabolic-syndrome composite improvement (fucoxanthin). López-Ramos 2023 (PMID 37405785) and other standalone fucoxanthin trials are typically 8 to 16 weeks.

12 to 24 weeks · body-composition signals. Baer 2011 (PMID 21677076) — 23-week free-living whey signal of ~1.8 kg body-weight and ~2.3 kg fat-mass reduction vs maltodextrin. The Miller 2014 meta-analysis (PMID 24724774) — energy-restriction trials typically at 8 to 16 weeks duration showing lean-mass preservation with adequate protein.

6 to 24 months · clinical weight-loss thresholds (5%, 10%, 15% body weight). These typically require sustained behavioral and dietary intervention. No ingredient on this page produces clinically meaningful weight loss as a standalone intervention.

  • GLP-1 Companion — lean-mass preservation during rapid weight loss; pre-meal whey GLP-1/GIP release mechanism overlap.
  • Athletic Performance — per-meal MPS framework (1.6 g/kg/day Morton 2018 PMID 28698222) is the shared structural anchor.
  • Heart Health — omega-3 TG-lowering and cardiometabolic overlap with the metabolic-syndrome composite.
  • Intermittent Fasting — energy-restriction lifestyle context.

Frequently Asked Questions

1. Does fucoxanthin actually cause weight loss?

The standalone evidence (López-Ramos 2023 PMID 37405785) is most robust on metabolic-syndrome composite markers rather than on isolated body-weight reduction. The Abidov 2010 Xanthigen NAFLD signal (PMID 19840063) is in a complex formulation (fucoxanthin + pomegranate seed oil), and should not be over-extrapolated to standalone fucoxanthin. The Mikami 2017 RCT (PMID 28620480) is most interesting for the UCP1 genotype interaction signal in HbA1c. The honest framing: fucoxanthin is a metabolic-syndrome composite-marker candidate with interesting UCP1 mechanism; it is not a guaranteed weight-loss agent.

2. Is yeast protein as good as whey for weight management?

For lean-mass preservation during energy restriction, the priority is total protein intake at 1.6 to 2.4 g/kg/day (Miller 2014 PMID 24724774). Yeast protein has PDCAAS near 1.00 (Cao 2024 PMID 39303477), placing it in the same protein-quality tier as whey on biomarker terms. Whey has the larger direct human muscle-endpoint RCT base (Baer 2011 PMID 21677076 chronic body composition); yeast protein has a smaller but transparently disclosed primary-human evidence base. The honest framing: yeast protein is a viable plant-fermentation option for amino-acid completeness, with the direct-RCT base still building.

3. Does berberine work like metformin?

The "berberine is nature's metformin" framing is a marketing claim, not an evidence-graded equivalence. Both engage AMPK at the mechanism level; the clinical-endpoint trials are not directly equivalent in magnitude or duration. This page does not reproduce specific berberine PMIDs from the broader literature. Discuss any glycemic management strategy with your prescribing physician.

4. Why is astaxanthin not on this page?

The Xia 2020 meta-analysis (PMID 32755613) reported non-significant pooled effects on BMI and body weight. Astaxanthin has substantial evidence for skin and fatigue but does not have weight-management evidence at the meta-analytic level — so it is intentionally not in this page's related-ingredients list. The negative-findings disclosure reflects this honest reading.

5. What about GLP-1 medications for weight management?

GLP-1 receptor agonist medications (semaglutide, tirzepatide, etc.) are a separate medical category from nutrition supplementation. The GLP-1 Companion page addresses the nutrition adjunct strategy for medication users — including the critical priority of protein adequacy for lean-mass preservation during rapid weight loss.

6. Does a whey pre-load really raise GLP-1 like the medications do?

Whey pre-load before a meal raises endogenous GLP-1 and GIP post-prandially (Jakubowicz 2014 PMID 25005331; Smith 2022 PMID 35618446) — but this is a transient picomole-per-liter peak measured for hours, mechanistically related to but categorically distinct from a prescription GLP-1 receptor agonist's sustained pharmacological agonism. The honest framing: whey pre-load is a real, measurable, and reproducible incretin-axis nutrition signal with glycemic-control and time-in-range support; it is not equivalent to medication and should not be marketed as such.

7. How much fiber actually matters for weight management?

The Reynolds 2019 Lancet systematic review (PMID 30638909) pooled prospective and trial evidence supporting roughly 25 to 29 g/day of total dietary fiber for cardiometabolic endpoints, with possible incremental benefit above that range. Most adults in the U.S. consume ~15 g/day, so even closing the gap to the recommended intake is the larger-effect intervention than adding a supplemental dose. Psyllium ~10 g/day reduces LDL-C by ~0.33 mmol/L (Jovanovski 2018 PMID 30239559); psyllium and pectin are the RCT-supported forms for chronic constipation (Van der Schoot 2022 PMID 35816465). Fiber is a structural pattern lever, not a fat-loss agent.

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

  1. PMID 37405785 · López-Ramos 2023 · standalone fucoxanthin RCT · metabolic-syndrome composite improvement
  2. PMID 19840063 · Abidov 2010 · Xanthigen complex (fucoxanthin + pomegranate seed oil) · NAFLD / body-weight signal (complex-formulation caveat)
  3. PMID 28620480 · Mikami 2017 · fucoxanthin RCT · HbA1c reduction interacting with UCP1 thrifty-allele genotype
  4. PMID 33809062 · Shih 2021 · LMF-HSFx complex (low-molecular-weight fucoidan + high-stability fucoxanthin) · NAFLD signal (complex-formulation caveat)
  5. PMID 39303477 · Cao 2024 · yeast protein PDCAAS ~1.00 protein-quality data
  6. PMID 40934397 · Qiao 2025 · INFOGEST yeast-protein DIAAS estimate 0.82 to 1.00
  7. PMID 41568030 · Van den Abbeele 2026 · ex-vivo gut-microbiota · yeast-protein gut-barrier / SCFA non-inferior to whey and soy
  8. PMID 21677076 · Baer 2011 · 56 g/day whey vs soy vs maltodextrin, 23 wk free-living · whey −1.8 kg body weight / −2.3 kg fat mass vs maltodextrin
  9. PMID 24724774 · Miller 2014 · energy-restriction protein meta-analysis · 1.6 to 2.4 g/kg/day for lean-mass preservation
  10. PMID 25005331 · Jakubowicz 2014 · whey pre-load · increased post-prandial GLP-1 / GIP, reduced glucose excursion in type 2 diabetes
  11. PMID 35618446 · Smith 2022 · whey premeal shot · 7-day free-living CGM time-in-range signal
  12. PMID 30638909 · Reynolds 2019 · dietary fiber and cardiometabolic outcomes · Lancet systematic review (cross-link context)
  13. PMID 30239559 · Jovanovski 2018 · psyllium LDL-C meta-analysis · ~0.33 mmol/L reduction at ~10.2 g/day (cross-link context)
  14. PMID 35816465 · Van der Schoot 2022 · fiber for chronic constipation meta-analysis · psyllium and pectin RCT-supported (cross-link context)
  15. PMID 23134885 · Cermak 2012 · protein + resistance training meta-analysis in older adults
  16. PMID 28698222 · Morton 2018 · protein-supplementation MPS meta-analysis · 1.6 g/kg/day threshold across adult age
  17. PMID 32755613 · Xia 2020 · astaxanthin meta-analysis · HDL-C significant · BMI / body-weight null (basis for astaxanthin exclusion)
  18. PMID 32438401 · mycoprotein MPS analogy (adjacent evidence category for yeast protein)
  19. PMID 33900466 · yeast β-glucan literature (adjacent evidence category for yeast protein)

Coverage Notes

This Weight Management page draws from three linked ingredient pages on asxan.ai (fucoxanthin, yeast-protein, berberine). Berberine's evidence is described qualitatively as preliminary / emerging in the evidence stack and treated as a mechanism candidate in How It Works, since this page does not reproduce PMIDs from outside the asxan.ai evidence base. The page also draws on the protein and whey-protein evidence (Baer 2011 PMID 21677076 chronic body-composition signal; Miller 2014 PMID 24724774 energy restriction) even though they are not in the related-ingredients frontmatter list — this is essential because the protein-adequacy framework is the structural anchor for healthy weight management. Astaxanthin is intentionally NOT in the related-ingredients list because Xia 2020 (PMID 32755613) reported non-significant pooled BMI / body-weight effects. Regulatory note: obesity (ICD-10 E66) is a clinical condition; no ingredient on this page substitutes for physician-led and dietitian-supported management.

← Home

Ask Agent Axor